Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with FLOT in Locally Advanced Gastric Cancer
NCT04891016Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2021
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological Complete Response Rate at 6 months. Started Jun 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04891016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891016.